Data as of:
Price 02-03-26 16:00 ET,
Balance Sheet 2025-09-30,
Income Statement 2025-09-30,
Cash Flow 2025-09-30
Indicators
Dividend indicators
Value
Date
Pays Dividend
No
2-1-2026
Income indicators
Value
Date
EBITDA Positive
No
2-1-2026
Net Income Positive
No
2-1-2026
Avg CA Burn (Annual %)
25.32%
2-1-2026
Avg CA Burn (Quarterly %)
-0.24%
2-1-2026
Shares Outstanding Changes
Date
Shares Outstanding
Delta
2025-11-07
41,116,640
+200,677
2025-09-17
40,915,963
-37
Short Interest Changes
Latest short interest:
4,783,862 shares
(12.21% of float)
| Days to cover: 5.51
Date
Short Interest
Delta
Δ %
2026-02-03
4,783,862 shares
+0
+0.00%
2026-02-02
4,783,862 shares
+0
+0.00%
2026-01-30
4,783,862 shares
None
—
Interesting Volume Days
Volume/ratio use shares outstanding as of the event date (frozen).
Date
Volume
Shares Outstanding
Volume / Shares
Price
No interesting volume events
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.